NCT04192695Completed
Esophageal Squamous Cell Cancer Surveillance With Cytosponge
Surveillance and Early Detection of Esophageal Squamous Cell Carcinoma With Minimally-invasive Cytosponge™ Cell Collection Device Coupled With Molecular Biomarkers
Source: ClinicalTrials.gov · Last updated 8 May 2024
Brief summary (registry, in English)
Surveillance and early detection of esophageal squamous cell carcinoma with minimally-invasive Cytosponge™ cell collection device coupled with molecular biomarkers.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 178 (actual)
- First submitted
- 12 Nov 2019
- Start date
- 1 Jan 2021
- Primary completion date
- 1 Feb 2024
- Lead sponsor
- Centre of Postgraduate Medical Education
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT04192695
What you commit to
- Study type: Interventional
- Participants enrolled: 178
- From 1 Jan 2021 to the primary completion date, 1 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients currently on anticoagulant treatment (warfarin, acenocoumarol) with no possibility of stopping / modification
Other illness
- History of myocardial infarction or other cardiovascular event within 6 months of enrolment
- Neurological diseases associated with impaired swallowing
- Patients in long-term care or institutional care (physical, psycho-social disorders, intellectual disability).
Other
- Dysphagia grade ≥3 (able to swallow only liquid foods)
Who the study is looking for
- Patients with esophageal squamous cell cancer (ESCC):
- Patients ≥18 years of with adequate performance status for endoscopy
- Newly diagnosed ESCC suitable for endoscopic or oncological treatment (Rth/Chth)
- Patients currently undergoing oncological treatment (Rth/Chth)
- Consent to provide tissue samples for the study
- Dysphagia grade ≤2 (able to swallow mixed foods and tablets)
- Patients at high risk for ESCC:
- Patients ≥18 years of age with adequate performance status for endoscopy
- Prior definitive treatment for head and neck cancer (cancer of the oral cavity, hypopharyngeal cancer, laryngeal carcinoma) and at least 12 months post-therapy (both Rth, Chth, and combination treatment)
- Prior definitive endoscopic treatment for early ESCC in the past (at least 6 months since completion)
- Consent to provide tissue samples for the study
- Dysphagia grade ≤2
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical Centre for Postgraduate Education Coordinator of this site? Confirm its status | Warsaw | Poland | Unknown status |
Related publications
- Feasibility and Diagnostic Accuracy of a Capsule-Sponge Device for Esophageal Squamous Neoplasia (EDEN Trial).Clin Gastroenterol Hepatol · 2026 · PMID 41628756
This page is information, not medical advice. Discuss any trial with your doctor.